Agenda

Please note all sessions listed in Pacific Time. Agenda and credit amount subject to change.

Download

Thursday, April 16

Day 1

6:45 am

Registration

7:15 am — 8:15 am

Breakfast & Non-CME/CE Bonus Presentation

Sponsored by Bristol Myers Squibb

8:25 am — 8:35 am

Conference Welcome

Hetty E. Carraway, MD, MBA
Daniel A. Pollyea, MD, MS
Eytan M. Stein, MD

8:35 am — 8:40 am

Session I: Advances in Myelodysplastic Syndromes and Precursor States

Session Introduction

Jacqueline S. Garcia, MD
Richard M. Stone, MD

8:40 am — 9:00 am

Controlling the Control: The Problem With Azacitidine Control Arms in MDS

Mikkael A. Sekeres, MD

9:00 am — 9:10 am

Audience Q&A

Jacqueline S. Garcia, MD
Richard M. Stone, MD
Mikkael A. Sekeres, MD

9:10 am — 9:30 am

When Should AZA/VEN Be Used in MDS? Insights from the VERONA Study

Jacqueline S. Garcia, MD

9:30 am — 9:40 am

Audience Q&A

Jacqueline S. Garcia, MD
Richard M. Stone, MD

9:40 am — 10:00 am

Should CCUS and High Risk CH Be Treated As Early MDS

Zoey Xie, MD, MS

10:00 am — 10:10 am

Audience Q&A

Jacqueline S. Garcia, MD
Richard M. Stone, MD
Zoey Xie, MD, MS

10:10 am — 10:30 am

Management of VEXAS and Myeloid Disorders: From Guidelines to Treatment Response Assessment

Uma Borate, MBBS

10:30 am — 10:40 am

Audience Q&A

Jacqueline S. Garcia, MD
Richard M. Stone, MD
Uma Borate, MBBS

10:40 am — 11:10 am

Exhibit and Poster Hall Opens

11:10 am — 11:50 am

Stump the Experts

MDS Expert - Michael K. Jones, MD
AML Expert - Mark Levis, MD, PhD
AML Fellow - Mary-Elizabeth Percival, MD, MS

11:50 am — 11:55 am

Session II: Pre-Clinical Translational Research

Session Introduction

Ravi Majeti, MD PhD
Daniel Starczynowski, PhD

11:55 am — 12:15 pm

Can Manipulation of Inflammation Lead to AML Fixation?

Shanshan Pei, PhD

12:15 pm — 12:25 pm

Audience Q&A

Ravi Majeti, MD PhD
Daniel Starczynowski, PhD
Shanshan Pei, PhD

12:25 pm — 12:45 pm

Nicotinamide: A Metabolic Opportunity for MDS?

Maria L. Amaya, MD, PhD

12:45 pm — 12:55 pm

Audience Q&A

Ravi Majeti, MD PhD
Daniel Starczynowski, PhD
Maria L. Amaya, MD, PhD

12:55 pm — 1:15 pm

Apelin as a Target in AML

Leonard Zon, MD

1:15 pm — 1:25 pm

Audience Q&A

Ravi Majeti, MD PhD
Daniel Starczynowski, PhD
Leonard Zon, MD

1:25 pm — 2:25 pm

Lunch & Non-CME/CE Bonus Presentation

Sponsored by Servier Pharmaceuticals

2:25 pm — 2:40 pm

Refreshments: Visit Exhibit and Poster Hall

2:40 pm — 2:45 pm

Session III: Novel Strategies in ALL

Session Introduction

Anjali S. Advani, MD
Wendy Stock, MD

2:45 pm — 3:05 pm

Newly Diagnosed Philadelphia Positive Acute Lymphablastic Leukemia Without a Transplant

Elias J. Jabbour, MD

3:05 pm — 3:15 pm

Audience Q&A

Anjali S. Advani, MD
Wendy Stock, MD
Elias J. Jabbour, MD

3:15 pm — 3:35 pm

Can CAR-T Cells Repalce Allergenic Stem Cell Transplant for High-Risk Acute Lymphablastic Leukemia

Noelle Frey, MD, MSCE

3:35 pm — 3:45 pm

Audience Q&A

Anjali S. Advani, MD
Wendy Stock, MD
Noelle Frey, MD, MSCE

3:45 pm — 4:00 pm

Break: Visit Exhibit and Poster Hall

4:00 pm — 4:05 pm

Session IV: Multidisciplinary Care

Session Introduction

Maya Abdallah, MD
B. Douglas Smith, MD

4:05 pm — 4:25 pm

Reflections on My AML Journey - A Coach's Insights

Matt Lubeck

4:25 pm — 4:35 pm

Audience Q&A

Maya Abdallah, MD
B. Douglas Smith, MD
Matt Lubeck

4:35 pm — 4:55 pm

The Singularity: How Can AI Be Used in the AML Field?

Jan Moritz Middeke, MD

4:55 pm — 5:05 pm

Audience Q&A

Maya Abdallah, MD
B. Douglas Smith, MD
Jan Moritz Middeke, MD

5:05 pm — 5:25 pm

Management of Infections in Patients With Leukemia Pre and/or Post BMT

Jessica Lum, MD

5:25 pm — 5:35 pm

Audience Q&A

Maya Abdallah, MD
B. Douglas Smith, MD
Jessica Lum, MD

5:35 pm — 6:35 pm

Reception & Non-CME/CE Bonus Presentation

6:35 pm — 7:35 pm

Welcome Reception

6:35 pm

Day One Adjourns

Friday, April 17

Day 2

7:00 am

Registration

7:30 am — 8:30 am

Breakfast & Non-CME/CE Bonus Presentation

8:30 am — 8:45 am

Break: Visit Exhibit and Poster Hall

8:45 am — 8:50 am

Session V: Acute Myeloid Leukemia

Session Introduction

Courtney D. DiNardo, MD, MSCE
Gary J. Schiller, MD

8:50 am — 9:10 am

Taking on TP53: What New Approaches to TP53+ AML Should Be Pursued?

David A. Sallman, MD

9:10 am — 9:20 am

Audience Q&A

Courtney D. DiNardo, MD, MSCE
Gary J. Schiller, MD
David A. Sallman, MD

9:20 am — 9:40 am

Lessons Learned From Exploring Mutational Profiles for Diverse Patients

Amir T. Fathi, MD

9:40 am — 9:50 am

Audience Q&A

Courtney D. DiNardo, MD, MSCE
Gary J. Schiller, MD
Amir T. Fathi, MD

9:50 am — 10:10 am

Dog Days of AML: What Canine AML Can Teach Us About Our AML Patients

Adam Harris, DMV, PhD, Dip. ACVP

10:10 am — 10:20 am

Audience Q&A

Courtney D. DiNardo, MD, MSCE
Gary J. Schiller, MD
Adam Harris, DMV, PhD, Dip. ACVP

10:20 am — 10:50 am

Refreshments and Non-CME/CE Bonus Presentation

11:20 am — 11:50 am

Break: Visit Exhibit and Poster Hall

10:50 am — 11:50 am

Independent CME Symposium

11:50 am — 1:00 pm

Session VI: Ernest Beutler Memorial Lecture

11:50 am — 12:00 pm

Introduction of the Ernest Beutler Memorial Lecture

12:00 pm — 12:50 pm

Ernest Beutler Memorial Lecture

12:50 pm — 1:00 pm

Audience Q&A

1:00 pm — 2:00 pm

Lunch & Non-CME/CE Bonus Presentation

Sponsored by Geron Pharmaceuticals

2:00 pm — 2:15 pm

Refreshments: Visit Exhibit and Poster Hall

2:15 pm — 2:20 pm

Session VII: Bone Marrow Transplant

Session Introduction

Lori Muffly, MD
Aaron P. Rapoport, MD

2:20 pm — 2:40 pm

ORCA T

Everett Meyer, MD

2:40 pm — 2:50 pm

Audience Q&A

Lori Muffly, MD
Aaron P. Rapoport, MD
Everett Meyer, MD

2:50 pm — 3:10 pm

What is the Best Way to Use MRD Information in AML in the Pre and Post BMT Setting

3:10 pm — 3:20 pm

Audience Q&A

Lori Muffly, MD
Aaron P. Rapoport, MD

3:20 pm — 3:40 pm

When Should We Use Maintenance Therapies for AML Post BMT?

Alexander Perl, MD

3:40 pm — 3:50 pm

Audience Q&A

Lori Muffly, MD
Aaron P. Rapoport, MD
Alexander Perl, MD

3:50 pm — 4:00 pm

Closing Remarks

4:00 pm

Conference Adjourns